Skip to main content

Advertisement

Log in

Escalating immunotherapy of multiple sclerosis

New aspects and practical application

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Recent clinical studies in multiple sclerosis (MS) provide new data on the treatment of clinically isolated syndromes, on secondary progression, on direct comparison of immunomodulatory treatments and on dosing issues. All these studies have important implications for the optimized care of MS patients. The multiple sclerosis therapy consensus group (MSTCG) critically evaluated the available data and provides recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence on MRI for subclinical dissemination of disease. Recent trials show that the efficacy of interferon beta treatment is more likely if patients in the secondary progressive phase of the disease still have superimposed bouts or other indicators of inflammatory disease activity than without having them. There are now data available, which suggest a possible dose-effect relation for recombinant beta-interferons. These studies have to be interpreted with caution, as some potentially important issues in the design of these studies (e. g. maintenance of blinding in the clinical part of the study) were not adequately addressed. A meta-analysis of selected interferon trials has been published challenging the value of recombinant IFN beta in MS. The pitfalls of that report are discussed in the present review as are other issues relevant to treatment including the new definition of MS, the problem of treatment failure and the impact of cost-effectiveness analyses. The MSTCG panel recommends that the new diagnostic criteria proposed by McDonald et al. should be applied if immunoprophylactic treatment is being considered. The use of standardized clinical documentation is now generally proposed to facilitate the systematic evaluation of individual patients over time and to allow retrospective evaluations in different patient cohorts. This in turn may help in formulating recommendations for the application of innovative products to patients and to health care providers. Moreover, in long-term treated patients, secondary treatment failure should be identified by pre-planned follow-up examinations, and other treatment options should then be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Barkhof F, Filippi M, Miller D, Scheltens P, Campi A, Polman C, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069

    Article  PubMed  Google Scholar 

  2. Bashir K, Buchwald L, Coyle P, Freedman M, Jeffery D, Markowitz C, et al. (2002) Optimizing immunomodulatory therapy for MS patients. Int J MS Care 8:3–7

    Google Scholar 

  3. Brex PA, Jenkins R, Fox NC, Crum WR, O’Riordan JI, Plant GT, et al. (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689–1691

    CAS  PubMed  Google Scholar 

  4. CHAMPS Study Group (2002) MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59:998–1005

    PubMed  Google Scholar 

  5. Clanet M, Radue E, Kappos L, Hartung H, Hohlfeld R, Sandberg-Wollheim M, et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507–1517

    CAS  PubMed  Google Scholar 

  6. Cohen J, Cutter G, Fischer J, Goodman A, Heidenreich F, Kooijmans M, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679–687

    CAS  PubMed  Google Scholar 

  7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582

    Article  CAS  PubMed  Google Scholar 

  8. Comi G, Filippi M, Wolinsky J, et al. (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290–297

    Article  CAS  PubMed  Google Scholar 

  9. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O (2002) Effect of early interferon treatment on conversion to definite multiple sclerosis: The ETOMS study-4 years results. Mult Scler 8(Suppl. 1):S8

    Google Scholar 

  10. Dalton C, Brex P, Miszkiel K, et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47–53

    Article  PubMed  Google Scholar 

  11. Delisse B, et al. (2004) Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 10:92

    CAS  PubMed  Google Scholar 

  12. De Stefano N, Narayanan S, Francis G, et al. (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70

    Article  CAS  PubMed  Google Scholar 

  13. Durelli L, Verdun E, Barero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). TLancet 359:1453–1460

    CAS  Google Scholar 

  14. European Study Group on Interferon beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497

    PubMed  Google Scholar 

  15. Fazekas F, Barkhof F, Filippi M, et al. (1999) The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53:448–456

    CAS  PubMed  Google Scholar 

  16. Filippini G, Munari L, Incorvaia B, et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552

    CAS  PubMed  Google Scholar 

  17. Ghalie R, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909–913

    CAS  PubMed  Google Scholar 

  18. Ghalie R, Mauch E, Edan G, et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8:441–445

    CAS  PubMed  Google Scholar 

  19. Gold R, Buttgereit F, Toyka K (2001) Mechanism of action of glucocorticoid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117:1–8

    Google Scholar 

  20. Goodin D, Frohman E, Garmany G, et al. (2002) Disease modifying therapies in multiple sclerosis—Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 58:169–178

    CAS  PubMed  Google Scholar 

  21. Hartung H, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018–2025

    Article  PubMed  Google Scholar 

  22. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904

    Article  CAS  PubMed  Google Scholar 

  23. Johnson K, Brooks B, Ford C, et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6:255–266

    Article  CAS  PubMed  Google Scholar 

  24. Keegan M, Pineda A, McClelland R, Darby C, Rodriguez M, Weinshenker B (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143–146

    Article  CAS  PubMed  Google Scholar 

  25. Khan O, Tselis A, Kamholz J, Garbern J, Lewis R, Lisak R (2001) A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing–remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7:349–353

    CAS  PubMed  Google Scholar 

  26. La Mantia L, et al. (2002) Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 4:CD002819

  27. Leary S, Miller D, Stevenson V, Brex P, Chard D, Thompson A (2003) Interferon beta-1a in primary progressive MS. Neurology 60:44–51

    CAS  PubMed  Google Scholar 

  28. Li D, Zhao G, Paty D, et al. (2001) Randomized controlled trial of interferonbeta 1a in secondary progressive MS. Neurology 56:1505–1513

    CAS  PubMed  Google Scholar 

  29. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528–1532

    PubMed  Google Scholar 

  30. McDonald W, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  31. Miller D, Khan O, Sheremata W, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23

    Article  CAS  PubMed  Google Scholar 

  32. MS-Therapie Konsensus Gruppe—MSTKG (1999) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371–386

    Article  PubMed  Google Scholar 

  33. National Multiple Sclerosis Society—NMSS (1998) Disease management consensus statement. Internet: www.nmss.org

  34. Noseworthy J, O’Brien P, Weinshenker B, et al. (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135–1143

    CAS  PubMed  Google Scholar 

  35. Noseworthy J, O’Brien P, Petterson T, et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514–1522

    CAS  PubMed  Google Scholar 

  36. Oger J, Freedman M, et al. (1999) Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in mutiple sclerosis. Can J Neurol Sci 26:294

    PubMed  Google Scholar 

  37. Optic neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Neurology 49:1404–1413

    PubMed  Google Scholar 

  38. O’Riordan J, Thompson A, Kingsley D, et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow-up. Brain 121:495–503

    PubMed  Google Scholar 

  39. Panitch H, Goodin D, Francis G, et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 59:1496–1506

    CAS  PubMed  Google Scholar 

  40. Poser CM, et al. (1983) New diagnostic criteria for multiple sclerosis.Guidelines for research protocols. Ann Neurol 13:227–230

    CAS  PubMed  Google Scholar 

  41. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and UBC MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56:1628–1636

    PubMed  Google Scholar 

  42. Report of the quality standards sub-committee of the American Academy of Neurology (1994) Practise advisory on selection of patients with multiple sclerosis for treatment with Betaseron®.Neurology 44:1537–1540

    PubMed  Google Scholar 

  43. Rieckmann P, Toyka KV, Austrian-German-Swiss multiple sclerosis therapy consensus group—MSTCG (1999) Escalating immunotherapy of multiple sclerosis. Eur Neurol 42:121–127

    CAS  PubMed  Google Scholar 

  44. Sellebjerg F, Nielsen H, Frederiksen J, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479–1484

    CAS  PubMed  Google Scholar 

  45. Sorensen PS (2001) ESIMS. European Charcot Foundation; Venice, 10–21, (Abstract)

  46. Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557–563

    Article  CAS  PubMed  Google Scholar 

  47. Sorensen PS, Ross C, Clemmesen M, et al. (2003) Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1181

    Article  CAS  PubMed  Google Scholar 

  48. Stangel M, Boegner F, Klatt C, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89–92

    Article  CAS  PubMed  Google Scholar 

  49. Sudlow C, Counsell C (2003) Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. Br Med J 326:388–392

    Google Scholar 

  50. The Once Weekly Interferon for MS Study Group—OWIMS (1999) OWIMS—Evidence of interferon beta-1a dose response in relapsing-remitting multiple sclerosis. Neurology 53:679–686

    PubMed  Google Scholar 

  51. Tintore M, Rovira A, Martinez M, et al. (2002) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21:702–706

    Google Scholar 

  52. Tintore M, Rovira A, Rio J, et al. (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30

    Article  CAS  PubMed  Google Scholar 

  53. Weinshenker B, O’Brien P, Petterson T, et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886

    CAS  PubMed  Google Scholar 

  54. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183–200

    CAS  PubMed  Google Scholar 

  55. Wolinsky JS, Toyka KV, Kappos L, Grossberg SE (2003) Interferon-beta antibodies: implications for the treatment of MS. Lancet Neurol 2:528

    PubMed  Google Scholar 

  56. Yudkin PL, Ellison GW, Ghezzi A (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051–1055

    CAS  PubMed  Google Scholar 

  57. Zivadinov R, Rudick R, De Masi R, et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239–1247

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to K. V. Toyka MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Multiple Sclerosis Therapy Consensus Group., Rieckmann, P. & Toyka, K.V. Escalating immunotherapy of multiple sclerosis. J Neurol 251, 1329–1339 (2004). https://doi.org/10.1007/s00415-004-0537-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-0537-6

Key words

Navigation